- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.04. | Boundless Bio presents preclinical data on cancer therapy BBI-940 | 2 | Investing.com | ||
| 17.04. | Boundless Bio, Inc.: Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 13.04. | Boundless Bio, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 17.03. | Boundless Bio, Inc.: Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| BOUNDLESS BIO Aktie jetzt für 0€ handeln | |||||
| 10.03. | Leerink reiterates Market Perform on Boundless Bio stock at $4 | 4 | Investing.com | ||
| 10.03. | Boundless Bio: Leerink bestätigt "Market Perform"-Rating und Kursziel von 4 US-Dollar | 3 | Investing.com Deutsch | ||
| 09.03. | Boundless Bio verringert Quartalsverlust und übertrifft Analystenerwartungen | 2 | Investing.com Deutsch | ||
| 09.03. | Boundless Bio GAAP EPS of -$0.58 misses by $0.12 | 1 | Seeking Alpha | ||
| 09.03. | Boundless Bio, Inc.: Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | 640 | GlobeNewswire (Europe) | KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1... ► Artikel lesen | |
| 09.03. | Boundless Bio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 09.03. | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.02. | Boundless Bio, Inc.: Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | 5 | GlobeNewswire (USA) | ||
| 20.01. | Boundless Bio, Inc.: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway | 2 | GlobeNewswire (USA) | ||
| 05.11.25 | Boundless Bio, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.11.25 | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.05.25 | Boundless Bio, Inc.: Boundless Bio Announces Portfolio Prioritization and Runway Extension | 439 | GlobeNewswire (Europe) | Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first... ► Artikel lesen | |
| 09.05.25 | Boundless Bio, Inc.: Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights | 394 | GlobeNewswire (Europe) | Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| EVOTEC | 5,350 | -0,93 % | ACHTUNG bei Evotec: Warum erfahrene Anleger zum Wochenstart die Reißleine ziehen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 21,860 | +4,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,008 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,508 | -0,45 % | Quantum Cyber Aligns Strategy With Trump Administration's National Cyber Security Framework, Targets Acquisitions in Quantum and Cyber Defense Sectors | BERKELEY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber (the "Company" or "Quantum Cyber"), today announced a strategic update in response... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,660 | +0,17 % | Intellia to report Phase 3 CRISPR gene editing trial results Monday | ||
| TEMPUS AI | 44,665 | +0,42 % | Tempus AI Nears Profitability as Operating Leverage Emerges | ||
| BIOCRYST PHARMACEUTICALS | 7,620 | -0,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,390 | +0,04 % | BioMarin Appoints Ian Clark As Board Chair | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), on Tuesday, announced the appointment of Ian Clark as Chair of the Board, subject to his election at the company's Annual Meeting... ► Artikel lesen | |
| ABIVAX | 96,10 | -1,64 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen |
BOUNDLESS BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,32 % bei einem Aktienkurs von 1,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOUNDLESS BIO INC finden Sie auf Wallstreet Online.